Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

The authors do not have any conflict of interests. We wish to thank F. Diez-Fuertes from the AIDS Immunopathology Unit (Instituto de Salud Carlos III, Centro Nacional de Microbiologia, Madrid, Spain) for help with the statistical analysis, Dr. R. Wagner from the Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University Regensburg (Regensburg, Germany) for 96ZM 651_HXB2_V3 SOSIP, Dr. Q. Sattentau from The Sir William Dunn School of Pathology, University of Oxford (Oxford, U. K.) for PGT151 antibody and pNL4-3 plasmid and antibodies 4E10, 2F5, 447-52D, VRC01, 5F3, b12, PG16 and 2G12 were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.